Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.

Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.
I
I

Ipsen

Balita

Reuters - 5 araw ang nakaraan

Ipsen, Foreseen Biotechnology Enter Licensing Agreement For Antibody-Drug Conjugate

BRIEF-Ipsen, Foreseen Biotechnology Enter Licensing Agreement For Antibody-Drug Conjugate July 11 (Reuters) - Ipsen SA IPN.PA : IPSEN AND FORESEEN BIOTECHNOLOGY ANNOUNCE EXCLUSIVE GLOBAL LICENSING AGREEMENT FOR ANTIBODY-DRUG CONJUGATE WITH FIRST-IN-CLASS POTENTIAL EXCLUSIVE GLOBAL RIGHTS SECURED FOR DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION OF
I
Reuters - 2 linggo ang nakaraan

Pearson, Softcat, Trelleborg

EUROPE RESEARCH ROUNDUP- Pearson, Softcat, Trelleborg July 5 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Pearson, Softcat and Trelleborg, on Friday. HIGHLIGHTS * Aker BP ASA AKRBP.OL : Jefferies cuts target price to NOK 340 from NOK 345 * GSK GSK.L : Citigroup cuts target price to 1900p from 2120p * Pearson PSON.L : Deutsche Bank raises target price to 1052p from 1050p * Softcat Plc SCTS.L : Jefferies cuts target price to 1,490p
A
A
B
C
C
D
D
E
E
G
I
K
N
N
P
T
T
T
V
W
A
D
Y
Reuters - 2 linggo ang nakaraan

Ipsen To Seek Marketing Authorizations For Cabometyx Outside Of U.S., Japan

BRIEF-Ipsen To Seek Marketing Authorizations For Cabometyx Outside Of U.S., Japan July 2 (Reuters) - Ipsen SA IPN.PA : IPSEN EXPANDS COLLABORATION AND LICENSE AGREEMENT FOR DEVELOPMENT OF CABOMETYX IN ADVANCED NEUROENDOCRINE TUMORS BASED ON POSITIVE CABINET PHASE III TRIAL DECISION ADDS TO EXISTING COLLABORATION AGREEMENT WITH EXELIXIS, PERMITTING IPSEN TO SEEK POTENTIAL MARKETING AUTHORIZATIONS FOR CABOMETYX OUTSIDE OF U.S.
I
Reuters - 1 buwan ang nakaraan

Ipsen’S Iqirvo® Receives U.S. FDA Accelerated Approval As A First-In-Class Ppar Treatment For Primary Biliary Cholangitis

BRIEF-Ipsen’S Iqirvo® Receives U.S. FDA Accelerated Approval As A First-In-Class Ppar Treatment For Primary Biliary Cholangitis Ipsen SA IPN.PA : IPSEN’S IQIRVO® RECEIVES U.S. FDA ACCELERATED APPROVAL AS A FIRST-IN-CLASS PPAR TREATMENT FOR PRIMARY BILIARY CHOLANGITIS IPSEN SA - IQIRVO MAY BE PRESCRIBED IMMEDIATELY IN U.S. FOR ELIGIBLE PATIENTS.
I
Reuters - 1 buwan ang nakaraan

US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug

UPDATE 3-US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug Adds details on pricing in paragraph 3, background throughout By Puyaan Singh and Mariam Sunny June 10 (Reuters) - The U.S. Food and Drug Administration granted accelerated approval to French drugmakers Ipsen IPN.PA and Genfit's GNFT.PA drug for a chronic inflammatory liver disease, Iqirvo, the companies said on Monday.
G
I
Reuters - 1 buwan ang nakaraan

US FDA approves Genfit and Ipsen's liver disease drug

US FDA approves Genfit and Ipsen's liver disease drug June 10 (Reuters) - The U.S. Food and Drug Administration has approved French drugmakers Ipsen IPN.PA and Genfit's GNFT.PA drug to treat a chronic inflammatory liver disease, Ipsen said on Monday. Reporting by Puyaan Singh in Bengaluru; Editing by Alan Barona
I
Reuters - 1 buwan ang nakaraan

Ipsen Initiates Share Buy-Back Program

BRIEF-Ipsen Initiates Share Buy-Back Program June 3 (Reuters) - Ipsen SA IPN.PA : IPSEN INITIATES A SHARE BUY-BACK PROGRAM TO COVER ITS FREE EMPLOYEE SHARE-ALLOCATION PLAN IPSEN APPOINTED AN INVESTMENT-SERVICES PROVIDER TO PURCHASE AN AGGREGATE NUMBER OF IPSEN S.A. SHARES UP TO 400,000, OR ABOUT 0.47% OF SHARE CAPITAL HAS APPOINTED AN INVESTMENT-SERVICES PROVIDER TO PURCHASE AN AGGREGATE NUMBER OF IPSEN S.A.
I
Reuters - 2 buwan ang nakaraan

Genfit Q1 Revenue Falls to EUR 1.1 Million

BRIEF-Genfit Q1 Revenue Falls to EUR 1.1 Million May 15 (Reuters) - Genfit SA GNFT.PA : REPORTED ON TUESDAY FIRST QUARTER 2024 FINANCIAL INFORMATION REVENUES FOR FIRST THREE MONTHS OF 2024 AMOUNTED TO EUR 1.1 MILLION COMPARED TO EUR 5.0 MILLION FOR SAME PERIOD IN 2023 AS OF MARCH 31, 2024, CO’S CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 74.0 MLN V
I
Reuters - 2 buwan ang nakaraan

Alfa Laval, OMV AG, Unilever Plc

EUROPE RESEARCH ROUNDUP- Alfa Laval, OMV AG, Unilever Plc May 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alfa Laval, OMV AG and Unilever Plc, on Tuesday. HIGHLIGHTS * Alfa Laval ALFA.ST : JP Morgan raises target price to SEK 385 from SEK 325 * Babcock International BAB.L : Citigroup raises target price to 640p from 530p * OMV AG OMVV.VI : Morgan Stanley raises to equal weight from underweight * SKAN Group AG SKAN.S : Baader
A
A
A
B
C
C
D
F
G
H
I
I
I
L
M
O
O
P
S
S
S
T
A
B
B
D
J
P
Reuters - 3 buwan ang nakaraan

Adidas, EFG International, Smith & Nephew

EUROPE RESEARCH ROUNDUP-Adidas, EFG International, Smith & Nephew May 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adidas, EFG International, and Smith & Nephew, on Thursday. HIGHLIGHTS * Adidas AG ADSGn.DE : Barclays raises target price to EUR 243 from EUR 231 * EFG International AG EFGN.S : Citigroup raises to buy from neutral * Gsk GSK.L : JP Morgan raises target price to 1660p from 1530p * Kemira Oyj KEMIRA.HE : Berenberg
3
A
A
A
C
E
E
G
H
H
H
I
K
L
M
N
P
S
T
W
A
J
P
T
Reuters - 3 buwan ang nakaraan

Ipsen Appoints Keira Driansky As EVP, President Of North America

BRIEF-Ipsen Appoints Keira Driansky As EVP, President Of North America May 2 (Reuters) - Ipsen SA IPN.PA : IPSEN APPOINTS KEIRA DRIANSKY AS EVP, PRESIDENT OF NORTH AMERICA Source text for Eikon: ID:nGNEbS43ZY Further company coverage: IPN.PA (Gdansk Newsroom)
I
Reuters - 3 buwan ang nakaraan

Barclays, JD Sports, Renault

EUROPE RESEARCH ROUNDUP- Barclays, JD Sports, Renault April 29 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Barclays, JD Sports and Renault, on Monday. HIGHLIGHTS * Barclays BARC.L : RBC raises target price to 260p from 255p * Hexagon HEXAb.ST : Morgan Stanley raises target price to SEK 105 from SEK 101 * JD Sports JD.L : Barclays cuts to equal weight from overweight * Renault RENA.PA : Berenberg raises target price to EUR 55 fr
A
A
A
A
B
B
C
C
C
D
D
E
E
E
E
G
H
I
I
J
N
P
R
S
S
S
W
A
A
E
S
Reuters - 3 buwan ang nakaraan

Ipsen rises after cancer treatment drives Q1 beat

BUZZ-Ipsen rises after cancer treatment drives Q1 beat ** Shares in Ipsen IPN.PA rise 3.2 % after the French biopharma company beat sales expectations in Q1 helped by its anti-cancer drug Cabometyx ** Q1 sales rise 13.3% in constant exchange rates to 822.4 million euros ($878.82 million), which Jefferies says is 4% ahead of consensus ** " Most key
I
Reuters - 3 buwan ang nakaraan

Ipsen Confirms Financial Guidance For 2024

BRIEF-Ipsen Confirms Financial Guidance For 2024 April 24 (Reuters) - Ipsen SA IPN.PA : CONFIRMATION OF FINANCIAL GUIDANCE FOR 2024 Q1 TOTAL-SALES GROWTH OF 13.3% AT CER(1), OR 10.9% AS REPORTED, DRIVEN BY 16.2%(1) INCREASE IN SALES OF GROWTH PLATFORMS Source text for Eikon: ID:nGNE5jc9nG Further company coverage: IPN.PA (Gdansk Newsroom)
I
Reuters - 3 buwan ang nakaraan

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch April 22 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. GTT GTT.PA : The French engineering company published on Friday consolidated revenues for Q1 up 81% at 144.8 million euros and confirmed its 2024 targets.
I
I
F
N
U
Reuters - 3 buwan ang nakaraan

Ipsen, Skyhawk Therapeutics Announce RNA Targeting Research Collaboration In Rare Neurological Diseases

BRIEF-Ipsen, Skyhawk Therapeutics Announce RNA Targeting Research Collaboration In Rare Neurological Diseases April 22 (Reuters) - Ipsen SA IPN.PA : IPSEN AND SKYHAWK THERAPEUTICS ANNOUNCE RNA TARGETING RESEARCH COLLABORATION IN RARE NEUROLOGICAL DISEASES IPSEN SA - UNDER TERMS OF AGREEMENT SKYHAWK IS ELIGIBLE TO RECEIVE UP TO $1.8 BILLION IPSEN SA
I

Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.